Cryo-Cell International, Inc.
CCEL
$4.20
-$0.10-2.33%
AMEX
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.99% | -1.42% | 1.49% | 1.87% | 2.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.99% | -1.42% | 1.49% | 1.87% | 2.50% |
| Cost of Revenue | -15.26% | -8.31% | -3.96% | -71.59% | -1.41% |
| Gross Profit | 1.40% | 0.90% | 3.43% | 201.89% | 3.98% |
| SG&A Expenses | -6.88% | 5.98% | 4.74% | 10.39% | 9.41% |
| Depreciation & Amortization | -4.57% | 217.89% | 478.01% | -30.25% | -30.82% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.26% | 1.46% | -1.68% | -31.71% | 1.38% |
| Operating Income | 36.74% | -12.17% | 28.59% | 96.96% | 8.27% |
| Income Before Tax | -14.05% | -60.94% | -32.83% | 94.73% | 29.25% |
| Income Tax Expenses | 33.03% | -73.14% | 5.29% | 121.22% | -15.22% |
| Earnings from Continuing Operations | -28.74% | -45.75% | -49.14% | 83.36% | 54.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.74% | -45.75% | -49.14% | 83.36% | 54.53% |
| EBIT | 36.74% | -12.17% | 28.59% | 96.96% | 8.27% |
| EBITDA | 31.05% | -3.80% | 43.72% | 103.38% | 0.86% |
| EPS Basic | -28.68% | -45.54% | -47.92% | 82.91% | 58.83% |
| Normalized Basic EPS | 60.90% | -37.03% | 11.48% | 76.79% | -19.59% |
| EPS Diluted | -30.77% | -50.00% | -55.36% | 82.91% | 62.50% |
| Normalized Diluted EPS | 62.80% | -36.45% | 10.51% | 76.79% | -20.19% |
| Average Basic Shares Outstanding | -0.05% | -0.46% | -2.36% | -2.66% | -2.71% |
| Average Diluted Shares Outstanding | -1.22% | -1.29% | -1.50% | -2.66% | -2.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |